Physician profile

Alan M Glover

Anesthesiology · Venice, FL

NPI 1346346947

$644.25

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$176.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Acutus Medical, INC. $138.75 2022
Sanara Medtech INC. $124.98 2021
Silk Road Medical, INC. $112.90 2023 Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent
Karl Storz Endoscopy-America $95.95 2020-2021
Nevro Corp. $94.43 2019
Medtronic, INC. $44.76 2023 Intellis Adaptivestim, Kyphon Express II Kyphopak Tray
Almatica Pharma LLC $19.19 2023 Gralise
Pfizer INC. $13.29 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alan M Glover

$644.25

in general payments reported 2019-2025

Years
2019-2023
Top company
Acutus Medical, INC.

https://glasscript.com/doctor/971125/alan-m-glover

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.